QUALITY MEDICINE FOR ALL
The global pharmaceutical market is characterized by the coexistence of varied quality standards : where patients in rich, strictly regulated countries can generally rely on the efficiency, safety and intrinsic quality of the medicines available to them, a large majority of people in resource-limited countries are at risk of receiving or buying poor quality pharmaceuticals. This difference is due to many reasons, among which we can mention :
– lack of resources from regulatory authorities in low- and middle-income countries (LMICs)
– the growing complexity and globalization of the pharmaceutical market
– the increasing pressure on prices to the detriment of a clear definition of the required quality standards
– limited awareness of the problem among key stakeholders, including some of the largest donors
– the lack of public and transparent information about the quality of medicines
– and finally the lack of political will at national and international level.
Although the problem posed by falsified medicines is the subject of a growing number of global initiatives, that of substandard drugs – the extent of which is very worrying in the LMICs – remains insufficiently taken into account. Substandard drugs, however, have at least as negative an impact on the health of vulnerable populations as falsified drugs.
OUR GOALS AND STRATEGY
To contribute to improving access to quality medicines, QUAMED is based on several strategic axes
The development of a network North / South to facilitate the sharing of reliable information on the sources of medicines and ease the communication between key players in pharmaceutical procurement. Rather than act independently the members plan their activities together relating to supplies and results of these activities are shared within the network via the database data.
Streamlining the use of resources by pooling skills as well as human and financial resources across the network.
The provision of recognized expertise in quality assurance and drug supply.
Any member of the association adheres to the QUAMED Charter and considers the access to quality essential drugs as a human right, universal and inalienable. QUAMED and its members commit themselves therefore to make every effort to improve procurement practices into the pharmaceutical industry and to participate in a wider awareness of the problem. QUAMED is not involved in any manufacturing activity, distribution or sales of drugs.
QUAMED is a non-profit association based in France (law 1901).
Quamed members (individuals and organisations) have extensive experience in the pharmaceutical, drug regulation and drug supply sectors in non-governmental organizations, international organizations and other institutions. They have worked, and continue to practice, in a wide variety of geographical and socio-economic contexts (Western Europe, Africa, Asia, Latin America and Eastern Europe) in collaboration with organizations such as WHO, the Global Fund , UNICEF, UNITAID and a large number of international NGOs and purchasing organisations.
In addition to the members, QUAMED has a network of external specialists that can be mobilized for consultations, technical support, physical or remote training sessions and other quality assurance related activities.
Board of Directors
The Board of Directors is made up of recognized professionals with extensive international experience in quality and access to medicines.
The executive is advised and guided for technical matters by the Technical Committee, a consultative body, composed of experienced professionals from the regulatory and industrial environment, from NGOs and from the United Nations. A total of 14 experts are members of the Technical Committee.
The QUAMED operational team is a small multifunctional team that combines experience and knowledge from different fields: pharmacy, economics, management, accounting, purchasing and supply chain management, quality assurance, administration and communication.